- Private Equity Bros
- Posts
- Private Equity Bros Weekly
Private Equity Bros Weekly
📊 Weekly Summary
A look at the top stories in finance and economics this week:
Central banks remain active, with the ECB cutting rates for the fourth time to 3% and Switzerland surprising markets with a 50 bps cut. China pledged increased fiscal spending to boost consumption, while UK GDP unexpectedly contracted by 0.1% in October, presenting challenges for Labour's growth agenda.
In the US, CPI rose by 2.7%, highlighting ongoing inflationary pressures. Global ETF assets soared to $15 trillion, driven by US investor inflows into equities. Meanwhile, Wall Street executives project M&A activity to surpass decade averages under the Trump administration.
Let’s break it down.
Real Deals, Real Exposure
📈 Recent Finance News
ECB cut rates for a fourth time to 3%: The euro initially fell against the dollar following the announcement (CNBC)
China pledged bigger fiscal spending to boost consumption: Yield on 10-year government bonds slid below 1.8% for first time (YF)
US CPI rose 2.7%, the most in seven months: Indicating persistent inflationary pressures despite Fed interventions (RT)
UK GDP shrinks unexpectedly by 0.1% in Oct: Underlines scale of challenge for Labour to get the economy growing (Guardian)
Global ETF assets soared to $15T: US leads inflows as investors shift from mutual funds and pour into Wall Street equities (FT)
US high-yield credit set for best returns in eight years: Driven by strong refinancing activity and risk-on sentiment (USN)
Goldman expects 2025 dealmaking to surpass 10-year averages: M&A activity set to increase under upcoming Trump administration (BT)
Switzerland cut rates by a surprise 50 bps to 0.5%: The bank also issued a new conditional inflation forecast (CNBC)
Wall Street hopes rate cuts will force clients out of cash in 2025: Cash in money markets rose by about $824 billion in 2024 (YF)
Trump advisers seek to shrink or eliminate bank regulators: Suggesting a possible shift in US financial oversight policies (RT)
Would You Take a Stake in a Life-Saving Breakthrough?
Pioneering medicine starts with investors like you.
Cizzle Biotech is transforming lung cancer detection with a patented, 95% accurate blood test. By joining our raise, you’ll gain ownership in a company backed by partnerships with Bio-Techne and Moffitt Cancer Center. You can build your portfolio with a stake in a medical breakthrough.
Read the Offering information carefully before investing. It contains details of the issuer’s business, risks, charges, expenses, and other information, which should be considered before investing. Obtain a Form C and Offering Memorandum at invest.cizzlebio.com
🔍 Newly Released Reports
What to Look for in a Purchase Price Allocation (Mercer Capital)
Maximizing M&A Success with Integration Strategies (PwC)
Accessing Private Markets through Evergreen Funds (FA)
The Role of LT Investors in Energy Transition (PwC)
Guide to Royalty Investing (Partners Group)
2025 Outlook (Morgan Stanley)
Impact Investing (World Bank)
🤝 M&A Activity
Axiata and Sinar Mas to merge Indonesian telecom units (YF)
Deal Value: $6.5B
Bain Capital increases offer for Fuji Soft (JT)
Deal Value: $4.3B
Patient Square Capital to take Patterson Companies private (YF)
Deal Value: $4.1B
Blackstone acquires Tokyo’s Garden Terrace Kioicho (Blackstone)
Deal Value: $2.6B
Bain Capital offers to buy Australia’s Insignia Financial (BT)
Deal Value: $1.7B
Saudi conglomerate Zahid Group offers to acquire Barloworld (AGBI)
Potential Deal Value: $1.3B
Warburg Pincus to acquire a 20% stake in UK United Trust Bank (BNN)
Potential Deal Value: $663M
Triton Partners to acquire Bosch's security systems operations (Triton)
Deal Value: Undisclosed
Healthcare company Bausch + Lomb explores a sale (FP)
Deal Value: Undisclosed
ReNew Energy Global considers privatization (BW)
Deal Value: Undisclosed
I hope you found this summary useful. We're actively gathering more insights to share with you soon.
Until next time,
PE Bro